Latest Period
Q4 2025
Security Snapshot
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) Institutional Ownership
CUSIP: 00461U105
13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026
Institutions Reporting
121
Shares (Excl. Options)
83,739,019
Price
$3.01
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.00001 par value
- Symbol
- ACRS on Nasdaq
- Shares outstanding
- 140,909,091
- Price per share
- $3.75
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 83,739,019
- Total reported value
- $252,051,583
- % of total 13F portfolios
- 0%
- Share change
- -3,756,315
- Value change
- -$10,906,422
- Number of holders
- 121
- Price from insider filings
- $3.75
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value is tracked under CUSIP 00461U105.
- 121 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 121 to 45 between Q4 2025 and Q1 2026.
- Reported value moved from $252,051,583 to $99,194,520.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 121 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 00461U105?
CUSIP 00461U105 identifies ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00461U105:
Significant Owners of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.9% | -17% | $52,312,500 | -$1,125,000 | 13,950,000 | -2.1% | BML Investment Partners, L.P. | 23 Apr 2026 |
| Bonita Biotech (HK) Ltd | 9.4% | $33,944,003 | 11,281,950 | Biosion, Inc. | 09 Dec 2025 | |||
| Deep Track Capital, LP | 7% | $33,735,450 | 9,345,000 | Deep Track Capital, LP | 09 Mar 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 6.3% | $28,600,144 | 7,626,705 | RA Capital Management, L.P. | 31 Mar 2026 | |||
| BlackRock, Inc. | 6.2% | +22% | $20,164,873 | +$3,698,306 | 6,700,629 | +22% | BlackRock, Inc. | 31 Dec 2025 |
| Adage Capital Management, L.P. | 4.9% | -34% | $10,028,474 | -$5,554,080 | 5,278,144 | -36% | Adage Capital Management, L.P. | 30 Sep 2025 |
| Rock Springs Capital Management LP | 4.7% | $7,720,853 | 5,046,309 | Rock Springs Capital Management LP | 31 Mar 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 3.5% | -32% | $5,449,080 | -$2,422,176 | 3,837,380 | -31% | Millennium Management LLC | 30 Jun 2025 |
As of 31 Dec 2025, 121 institutional investors reported holding 83,739,019 shares of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS). This represents 59% of the company’s total 140,909,091 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 10% | 14,250,000 | 0% | 38% | $42,892,500 |
| Vivo Capital, LLC | 6.3% | 8,888,888 | 0% | 1.7% | $26,755,553 |
| BlackRock, Inc. | 4.8% | 6,804,841 | +20% | 0% | $20,482,572 |
| VANGUARD GROUP INC | 4.6% | 6,502,080 | -0.21% | 0% | $19,571,260 |
| Rock Springs Capital Management LP | 3.2% | 4,453,741 | -3.4% | 0.69% | $13,405,760 |
| Decheng Capital LLC | 2.9% | 4,041,736 | 0% | 1.6% | $12,165,625 |
| MORGAN STANLEY | 2.4% | 3,415,390 | -16% | 0% | $10,280,323 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.4% | 3,371,000 | -36% | 0.02% | $10,146,710 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 2,392,772 | +0.14% | 0% | $7,204,302 |
| ACADIAN ASSET MANAGEMENT LLC | 1.5% | 2,122,399 | -8.8% | 0.01% | $6,385,000 |
| D. E. Shaw & Co., Inc. | 1.5% | 2,096,651 | -12% | 0% | $6,310,920 |
| KOTLER KEVIN | 1.2% | 1,705,929 | 0% | 3.8% | $5,134,846 |
| Palo Alto Investors LP | 1.1% | 1,566,840 | 0% | 0.66% | $4,716,188 |
| STATE STREET CORP | 1.1% | 1,506,403 | +35% | 0% | $4,534,273 |
| Connor, Clark & Lunn Investment Management Ltd. | 1% | 1,434,164 | +34% | 0.01% | $4,316,834 |
| CITADEL ADVISORS LLC | 0.86% | 1,205,281 | -16% | 0% | $3,627,895 |
| RENAISSANCE TECHNOLOGIES LLC | 0.8% | 1,125,331 | -31% | 0.01% | $3,387,246 |
| MILLENNIUM MANAGEMENT LLC | 0.75% | 1,053,246 | -32% | 0% | $3,170,270 |
| DEUTSCHE BANK AG\ | 0.7% | 987,351 | +6.9% | 0% | $2,971,927 |
| Aldebaran Capital, LLC | 0.68% | 954,262 | -3.4% | 2.6% | $2,872,329 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.65% | 916,846 | +2430% | 0% | $2,759,706 |
| Bollard Group LLC | 0.57% | 804,445 | -34% | 0.06% | $2,421,000 |
| Woodline Partners LP | 0.53% | 742,009 | 0.01% | $2,233,447 | |
| Three Bridge Wealth Advisors, LLC | 0.51% | 714,823 | 0% | 0.57% | $2,151,617 |
| NORTHERN TRUST CORP | 0.47% | 664,258 | -5.2% | 0% | $1,999,417 |
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 26,452,825 | $99,194,520 | +$1,374,125 | $3.75 | 45 |
| 2025 Q4 | 83,739,019 | $252,051,583 | -$10,906,422 | $3.01 | 121 |
| 2025 Q3 | 85,675,311 | $162,782,120 | -$11,317,612 | $1.90 | 103 |
| 2025 Q2 | 91,862,480 | $130,443,350 | -$2,093,251 | $1.42 | 95 |
| 2025 Q1 | 92,164,636 | $141,009,418 | +$2,108,864 | $1.53 | 106 |
| 2024 Q4 | 87,478,919 | $216,988,373 | +$93,728,957 | $2.48 | 97 |
| 2024 Q3 | 50,891,008 | $58,523,068 | -$1,742,222 | $1.15 | 76 |
| 2024 Q2 | 52,848,132 | $58,129,308 | -$1,619,597 | $1.10 | 93 |
| 2024 Q1 | 54,386,842 | $67,436,941 | -$3,788,067 | $1.24 | 93 |
| 2023 Q4 | 58,449,543 | $61,369,526 | -$207,123,774 | $1.05 | 102 |
| 2023 Q3 | 70,071,814 | $479,974,125 | -$28,113,579 | $6.85 | 137 |
| 2023 Q2 | 71,014,841 | $736,442,996 | +$5,835,766 | $10.37 | 131 |
| 2023 Q1 | 71,610,627 | $579,302,266 | +$19,605,105 | $8.09 | 148 |
| 2022 Q4 | 65,900,596 | $1,037,946,141 | -$2,542,115 | $15.75 | 126 |
| 2022 Q3 | 63,675,444 | $1,002,225,041 | +$5,530,098 | $15.74 | 124 |
| 2022 Q2 | 63,269,555 | $883,318,693 | +$55,162,166 | $13.96 | 112 |
| 2022 Q1 | 59,295,213 | $1,021,908,185 | +$59,352,437 | $17.24 | 107 |
| 2021 Q4 | 56,045,310 | $814,890,981 | -$39,784,690 | $14.54 | 133 |
| 2021 Q3 | 56,785,960 | $1,022,155,424 | +$15,328,009 | $18.00 | 126 |
| 2021 Q2 | 56,004,936 | $983,410,407 | +$20,628,850 | $17.56 | 128 |
| 2021 Q1 | 45,417,666 | $1,298,594,000 | +$509,363,836 | $25.20 | 95 |
| 2020 Q4 | 31,934,018 | $206,591,000 | +$27,717,112 | $6.47 | 79 |
| 2020 Q3 | 25,553,008 | $65,673,000 | -$3,889,513 | $2.57 | 52 |
| 2020 Q2 | 28,456,883 | $46,099,261 | -$5,512,533 | $1.62 | 56 |
| 2020 Q1 | 32,079,500 | $33,361,056 | +$3,161,589 | $1.04 | 65 |
| 2019 Q4 | 30,811,789 | $58,227,600 | +$3,325,295 | $1.89 | 72 |
| 2019 Q3 | 29,070,550 | $31,395,961 | -$19,214,772 | $1.08 | 76 |
| 2019 Q2 | 35,610,940 | $77,957,966 | -$16,270,841 | $2.19 | 82 |
| 2019 Q1 | 37,867,320 | $227,075,061 | -$11,074,522 | $5.99 | 91 |
| 2018 Q4 | 39,079,487 | $288,764,092 | +$36,606,178 | $7.39 | 95 |
| 2018 Q3 | 29,659,351 | $430,705,323 | -$29,549,131 | $14.52 | 81 |
| 2018 Q2 | 30,998,695 | $618,964,700 | +$11,707,281 | $19.97 | 92 |
| 2018 Q1 | 30,570,960 | $535,621,157 | +$33,812,143 | $17.52 | 100 |
| 2017 Q4 | 28,517,743 | $703,264,074 | -$10,560,834 | $24.66 | 102 |
| 2017 Q3 | 28,502,689 | $696,914,157 | +$73,632,695 | $25.81 | 102 |
| 2017 Q2 | 25,609,895 | $694,432,125 | +$43,716,393 | $27.12 | 101 |
| 2017 Q1 | 23,711,078 | $707,195,746 | +$74,703,828 | $29.82 | 111 |
| 2016 Q4 | 21,351,804 | $579,490,455 | +$95,769,317 | $27.14 | 100 |
| 2016 Q3 | 15,510,238 | $397,182,894 | +$4,351,904 | $25.61 | 59 |
| 2016 Q2 | 15,355,135 | $283,613,231 | +$13,304,019 | $18.47 | 47 |
| 2016 Q1 | 14,605,233 | $276,749,000 | +$2,035,314 | $18.95 | 34 |
| 2015 Q4 | 10,288,500 | $277,169,982 | +$277,169,982 | $26.94 | 33 |